African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians

Journal of Viral Hepatitis

Volumn 8, Issue 4, 2001, Pages 264-269

  Kinzie, J L ^a,b   Naylor, P H ^a,b   Nathani, M G ^a,b   Peleman, R R ^a,b   Ehrinpreis, M N ^a,b   Lybik, M ^a,b   Turner, J R ^a,b   Janisse, J J ^a,b   Massanari, M ^a,b   Mutchnick, M G ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Hepatitis C; Interferon; Race

Indexed keywords

ALPHA2B INTERFERON; RECOMBINANT ALPHA2B INTERFERON; VIRUS RNA;

ADULT; ARTICLE; CAUCASIAN; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RACE DIFFERENCE; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADULT; AFRICAN AMERICANS; AFRICAN CONTINENTAL ANCESTRY GROUP; CHRONIC DISEASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RNA, VIRAL; UNITED STATES;

EID: 0034914179     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2001.00292.x     Document Type: Article

References (29)

1. Hepatitis C: Global prevalence
2. An update on liver transplantation in the United States. Recent characteristics and outcome
3. Treatment of chronic hepatitis C with recombinant interferon alpha: A multicenter randomized, controlled trial
4. Consensus interferon: A novel interferon for the treatment of hepatitis C
5. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
6. Ribavarin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C
7. Combined treatment with interferon-alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone
8. Is there an optimal time to measure quantitative HCV RNA to predict non-response following interferon treatment for chronic HCV infection?
9. Quantification of initial decline of serum hepatitis C virus RNA and response to interferon alpha
10. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic hepatitis C
11. Discordance between serum alanine aminotransferase (ALT) and virologic response to IFN-alpha2b in chronic hepatitis C patients with high and low pretreatment serum hepatitis C virus RNA
12. Prediction of response during interferon alpha 2B therapy in chronic hepatitis C patients using viral and biochemical characteristics: A comparison
13. Prediction of successful outcome in a randomised controlled trial of the long-term efficacy of interferon alpha treatment for chronic hepatitis C
14. Racial differences in response to therapy with interferon in chronic hepatitis C
15. Viral and host factors in the prediction of response to interferon-alpha therapy in chronic hepatitis C after long-term follow-up
16. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C
17. Ultrarapic hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy
18. Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C
19. Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha-interferon therapy
20. Parameters predicting response to alpha-interferon treatment in chronic hepatitis C
21. The clinical value of grading and staging scores for predicting a long-term response and evaluating the efficacy of interferon therapy in chronic hepatitis C
22. Genotype, viral load and age as independent predictors of treatment outcome of interferon-alpha 2a treatment in patients with chronic hepatitis C. Construct group
23. Predictors of response to interferon therapy
24. Chronic hepatitis C and interferon alfa therapy: Predictors of long term
25. Genotype, serum level of hepatitis C virus RNA and liver histology as predictors of response to interferon-alpha 2a therapy in Japanese patients with chronic hepatitis C
26. Serum HCV RNA levels as determinants for the dose escalation of interferon; results from studies in an urban clinic population
27. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: Effects of higher doses of interferon and ribavirin combination therapy
28. The impact of interferon plus ribivarin on response to therapy in black patients with chronic hepatitis C